Colorectal cancer (CRC) is the second leading cause of cancerrelated death among men and women in Western countries. Once a tumour develops, a differentiated prognosis could be determined by lifestyle habits or inherited and somatic genetic factors. Finding such prognostic factors will be helpful in order to identify cases with a shorter survival or at a higher risk of recurrence that may benefit from more intensive treatment and follow-up surveillance. Sixteen CRC genetic susceptibility variants were directly genotyped in a cohort of 1235 CRC patients recruited by the EPICOLON Spanish consortium. Univariate Cox and multivariate regression analyses were performed taking as primary outcomes overall survival (OS), disease-free survival and recurrence-free interval. Genetic variants rs9929218 at 16q22.1 and rs10795668 at 10p14 may have an effect on OS. In conclusion, CRC susceptibility variants rs9929218 and rs10795668 may exert some influence in modulating patient's survival and they deserve to be further tested in additional CRC cohorts in order to confirm their potential as prognosis or predictive biomarkers.
Introduction
Colorectal cancer (CRC) is the second leading cause of cancer-related death among men and women in Western countries (1) . Despite recent improvements in CRC survival, it still remains a major public health problem with over 1 million cases worldwide and a disease-specific mortality of approximately 33% in the developed world. Moreover, a considerable portion of successfully treated CRC patients develop a recurrence or metastasis within 5 years of diagnosis (2) . It remains as an important aim for the management of CRC to understand why some patients relapse or respond to chemotherapy treatment, whereas others do not.
The main CRC prognostic marker used in clinical practice at present is tumour stage at diagnosis [tumour, node, metastasis (TNM)], which represents depth of tumour invasion, number of affected lymph nodes and distant metastasis (3) . Environmental factors such as smoking and diet, as well as some inherited genetic variants, are undoubtedly major risk factors for CRC, and likewise, several factors are known to influence CRC prognosis. Some studies reported that lifestyle factors, such as diet, physical activity and body mass index, influence tumour systemic inflammatory response, which affects cancer survival (4, 5) . Also, CRC genetic heterogeneity is known to influence patient's survival after diagnosis and the most studied markers of CRC prognosis have been somatic changes with a potential effect on cancer outcome. For instance, it is known that chromosomal instability is associated with a worse CRC prognosis, and microsatellite instability (MSI) and wild-type BRAF with a better prognosis (6, 7) . Additionally, inherited polymorphisms may have also the potential to affect CRC outcome. In fact, there is some evidence of familial concordance for survival in CRC, suggesting that inherited genetic variation can contribute to CRC prognosis (8) . Several studies have reported associations with inherited genetic factors and CRC outcome, including single nucleotide polymorphisms (SNPs) in the mismatch repair genes (9), microRNA-related genes (10) and toll-like receptor genes (11 (12) (13) (14) (15) (16) . Besides affecting CRC predisposition, it could be plausible that these variants may also have a role in CRC prognosis. This hypothesis has been explored by previous studies to some extent, including several of these genetic variants in their analyses, but reaching contradictory results (17) (18) (19) . Tenesa et al. (17) analysed 10 CRC susceptibility variants (rs16892766 at 8q23.3, rs6983267 at 8q24.21, rs10795668 at 10p14, rs3802842 at 11q23.11, rs4444235 at 14q22.2, rs4779584 at 15q13.3, rs9929218 at 16q22.1, rs4939827 at 18q21.1, rs10411210 at 19q13 and rs961253 at 20p12.3) in 2838 CRC cases and reported no association between them and allcause or CRC-specific mortality after diagnosis. A subsequent report by Xing et al. (18) described the analysis of six CRC susceptibility loci (rs16892766, rs6983267, rs10795668, rs3802842, rs4779584 and rs4939827) and their association with recurrence and death in a reduced number of cases (n = 380), suggesting that rs10795668 at 10p14 might be used as a survival biomarker to identify patients with a high risk of recurrence after chemotherapy. Very recently, Phipps et al. (19) examined the association between 16 CRC susceptibility variants (those analysed by Tenesa et al. (17) and rs6691170 and rs6687758 at Abbreviations: CI, confidence interval; CRC, colorectal cancer; DFS, disease-free survival; HR, hazard ratio; MSI, microsatellite instability; OS, overall survival; RFI, recurrence-free interval; SNPs, single nucleotide polymorphisms; TNM, tumour, node, metastasis.
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1q41, rs10936599 at 3q26.2, rs7136702 and rs11169552 at 12q13.3, rs4925386 at 20q13.33, whereas rs4813802 at 20p12.3 and rs1957636 at 14q22.2 were not included) and survival in 2611 cases, concluding that rs4779584 variant at 15q13.3 could affect progression of CRC. It should be noted that CRC susceptibility variants with positive results in Xing et al. (18) and Phipps et al. (19) were included in the study by Tenesa et al. (17) , so results are not concordant between these studies. Hence, the prognosis significance of these CRC susceptibility variants remains controversial. Therefore, the aim of this study was to evaluate the prognostic or predictive value of 16 CRC genetic susceptibility SNPs in our population-based cohort of 1235 CRC patients in order to identify cases with worse clinical outcome that may benefit from more intensive treatment and follow-up surveillance.
Materials and methods

Patients
We included 1235 CRC cases recruited by the EPICOLON consortium, a Spanish epidemiologic, prospective, multicentre and population-based study (20, 21) . Patients were selected from this cohort for whom follow-up data were available with a median follow-up of 36 months (range 0-72 months). Patients with inflammatory bowel disease, biallelic MUTYH mutations, Lynch syndrome (germline mutation carriers) or familial adenomatous polyposis were excluded. Colon cancer patients had received adjuvant or palliative 5-fluorouracil or FOLFOX-based chemotherapy, whereas rectal cancer patients had undergone 5-fluorouracil or FOLFOX-based chemotherapy or a combination of these regimens with radiation therapy.
Clinical characteristics considered in this study included gender, age, CRC location, TNM stage, chemotherapy treatment and tumour features such as MSI, histology type (adenocarcinoma and mucinous/signet-ring differentiation), degree of differentiation and presence of tumour-infiltrating lymphocytes.
This study was approved by the institutional ethics committee of each participant hospital in EPICOLON, and written informed consent was obtained from all patients.
Genotyping
Sixteen SNPs previously associated with CRC risk were genotyped in this study including rs6691170 (1q41), rs10936599 (3q26.2), rs16892766 (8q23.3), rs6983267 (8q24.21), rs10795668 (10p14), rs3802842 (11q23.1), rs11169552 (12q13.13), rs4444235 and rs1957636 (14q22.2), rs4779584 (15q13.3), rs9929218 (16q22.1), rs4939827 (18q22.1), rs10411210 (19q13), rs961253 and rs4813802 (20p12.3), and rs4925386 (20q13.33; Supplementary Table 1 , available at Carcinogenesis Online). Genotyping was performed using germline DNA from all cases and TaqMan allelic discrimination (Applied Biosystems) or single-base primer extension chemistry matrix-assisted laser desorption/ionization time-of-flight mass spectrometry detection (Sequenom Inc, San Diego, CA) according to the manufacturer's instructions. Genotyping was performed directly for all SNPs and genotypes were never based on imputation. Successful genotyping rate was >97% for all included SNPs.
Statistical analysis
The genotype distributions of all SNPs did not deviate significantly from that expected for a population in Hardy-Weinberg equilibrium. There was no sign of underlying population stratification in EPICOLON as tested by an independent study (21) .
The study endpoints were (i) overall survival (OS), defined as the time from diagnosis to death by any cause, patients alive being censored at the last follow-up visit; (ii) disease-free survival (DFS), defined as the time from diagnosis until radiologic evidence of disease recurrence or death from any cause, patients alive without tumour recurrence being censored at the last follow-up contact and (iii) recurrence-free interval (RFI), defined as the time from diagnosis until radiologic evidence of disease recurrence. For RFI, patients who died without known tumour recurrence were censored at the last follow-up visit. Patients with TNM stage IV tumours were not considered when analyzing RFI and DFS.
Univariate Cox regression analyses were performed on each covariate to examine its influence on prognosis, computing hazard ratio (HR) with the corresponding 95% confidence interval (95% CI). Every SNPs was included independently in the univariate analysis and evaluated under genotypic and dominant genetic models, considering risk alleles as defined by results of previous genome-wide association studies for CRC incidence (12) (13) (14) (15) 
Results
A total of 1235 cases with follow-up data available were included. Table I summarizes their demographic and clinical characteristics. In 845 patients (68, 42%), the tumour was located in the colon, and in 381 patients (3, 85%), the tumour was located in the rectum; most of the patients were in TNM stages II-III (833, 67.45%), and around half of all CRC cases received chemotherapy (581, 47.04%).
After a median follow-up of 36 months (range 0-72 months) in the whole cohort, there were 433 (35.1%) events for OS analysis. DFS and RFI analyses were based on 1001 CRC patients with stage I-III disease. With a median follow-up period of 40 months (range 1-72 months), 351 (35.1%) patients had died or showed disease recurrence, and there were 225 (22.6%) events for RFI analyses.
SNP genotypes were analysed by Cox regression in a univariate model taking into account genotypic and dominant inheritance in order to test their putative influence on OS, DFS and RFI. Results are summarized in Supplementary Table 2, available at Carcinogenesis Online. To proceed with the multivariate analysis, SNPs with a P < 0.2 for OS, DFS and RFI in the univariate analysis were further tested and covariates with a P > 0.2 were not further analysed.
Results for multivariate analyses are shown in Table II . Regarding OS adjusted for gender, age, TNM stage and chemotherapy treatment, both rs9929218 and rs10795668 remained statistically significant with a P < 0.05. The G allele of rs9929218 seemed to be linked with a However, it should be noted that these results should be not considered formally significant if Bonferroni correction for multiple testing was applied (P < 0.003125). Finally, there were no statistically significant associations in the DFS and IFR analyses. Further analyses were performed in a subset of patients in order to specifically evaluate the role of rs10795668 and rs9929218 on the benefit from chemotherapy as summarized in Table III . In a multivariate analysis performed in CRC patients treated with chemotherapy, OS seemed to be different depending on rs10795668 genotype, showing a borderline significant association between better outcome and the G allele (GG genotype, genotypic model: HR = 0.62, 95% CI 0.38-1.04, P = 0.0679; GG/GA genotypes, dominant model: HR = 0.57, 95% CI 0.34-0.97, P = 0.0384). On the other hand, in patients who did not receive chemotherapy, rs10795668 was not associated with clinical outcome (GG genotype: HR = 0.74, 95% CI 0.50-1.10, P = 0.4457; GG/GA genotypes: HR = 0.74, 95% CI 0.50-1.10, P = 0.1394). Likewise, in the stratified analysis by chemotherapy for rs9929218, we found that the effect of this SNP on OS remained borderline significant in patients treated with chemotherapy (GG genotype: HR = 0.58, 95% CI 0.34-1.01, P = 0.0531; GG/GA genotypes: HR = 0.60, 95% CI 0.36-1.02, P = 0.0601), but not in those not receiving chemotherapy (GG genotype: HR = 0.67, 95% CI 0.42-1.07, P = 0.0963; GG/GA genotypes: HR = 0.71, 95% CI 0.45-1.12, P = 0.1439).
Discussion
In addition to influencing the risk of developing CRC, inherited genetic variants may play a role in determining the natural course of the disease and therapeutic response. Identification of inherited polymorphisms as prognostic biomarkers in CRC may allow using them in order to identify cases at higher probability of relapse or worse clinical outcome that may benefit from more intensive treatment and follow-up surveillance.
This study evaluated the prognostic or predictive value of the 16 CRC genetic susceptibility variants in a cohort of 1235 CRC patients from Spain. It is worth mentioning that the genetic variants evaluated in this study corresponded to all known SNPs for CRC genetic susceptibility except for four of them that were identified very recently. Thus, this analysis corresponds to the more complete study up to now since it included the highest number of variants and used always direct genotyping. Phipps et al. (19) genotyped 14 variants (rs4813802 and rs1957636 were not included) and used imputation for some SNPs.
Our results demonstrate that both rs9929218 and rs10795668 are independently associated to OS in CRC patients. Thus, the G allele of both rs9929218 and rs10795668 seemed to be linked with improved OS. Interestingly, we also performed a subanalysis in a subgroup of patients in order to know the predictive role of rs9929218 and rs10795668 on treatment efficacy. In this stratified analysis, we found that the effect of both SNPs on OS seemed more evident in patients treated with chemotherapy than in those not receiving chemotherapy. These results, if validated, could suggest a beneficial response to chemotherapy for patients carriers of the G allele of both rs9929218 and rs10795668 compared with patients carriers of the A allele. However, it should be mentioned that statistical power was limited in these stratified analyses and results should be taken into account as exploratory and further tested in additional CRC cohorts. rs9929218 localizes to intron 1 of the CDH1 gene (also known as E-cadherin) at 16q22.1, a gene with an established role in CRC. Loss of CDH1 expression is an indicator of high tumour aggressiveness and it seems to be associated with factors of poor CRC prognosis such as vascular invasion, presence of lymph node metastases, advanced stages and poor tumour differentiation (22) . The G allele of rs9929218 was linked to a higher CRC risk by previous studies (12) , and it seemed to be linked with a better OS in this study. Then, it could be hypothesized that this association may be driven through a minimal downregulation of this gene. On the other hand, rs10795668 maps to an 82 kb linkage disequilibrium block within 10p14, but no known or predicted protein-coding genes are present in the 400 kb region harbouring this SNP. This genetic variant was reported to be associated with CRC risk in the European population (12) and it seemed to confer a better clinical outcome in this study.
So far, four studies have investigated the association between CRC susceptibility variants with disease progression and survival. Although there is some overlap in variants and outcomes, there are also some differences that may explain the lack of agreement between them. However, we found some coincidences after careful examination of results in previous studies that may be reinforcing our conclusions. Phipps et al. (19) found that the G allele of rs10795668 was associated with better OS in a multivariate analysis adjusted for gender, age and TNM stage in agreement with our results although this association was not statistically significant after Bonferroni correction (HR = 1.14, 95% CI 1.02-1.28, P = 0.02). They also reported a borderline association between the G allele of rs9929218 and improved OS after CRC diagnosis (HR = 1.12, 95% CI 0.99-1.26, P = 0.07). Likewise, Tenesa et al. (17) observed a trend of decreased all-cause mortality after adjustment for age and gender in patients carrying the G allele of rs9929218 (HR = 0.91, 95% CI 0.83-1.01, P = 0.08).
Interestingly, for both rs9929218 and rs10795668, we found a suggestive evidence of association with OS, but this association was not present in DFS and RFI analyses, suggesting that SNPs might act differentially on initiation and progression of CRC. Therefore, both rs9929218 and rs10795668 could have some influence on the aggressiveness of colorectal tumours.
Finally, this study has some limitations. First, it should be commented that our cohort sample size is probably not large enough to be able to reach stronger conclusions for the analysed variants. Also, as our results should be formally considered not statistically significant when applying multiple testing correction, additional studies in other CRC cohorts are needed in order to confirm the potential role of susceptibility variants in patient outcome. Second, the follow-up period used in this study may be causing a higher degree of censored cases. Third, we included clinical variables in our multivariate analysis that are well established as predictors of patients' outcome such TNM stage and chemotherapy treatment. However, although a number of studies have demonstrated that CRC with MSI have improved prognosis, we did not take into consideration tumours' MSI status in this analysis, due to the high percentage of missing data in our cohort. In addition, a more homogenous CRC cohort consisting of only stage II-III or MSS tumours may have provided more consistent results. Finally, patients included in this study did not receive the same first-line chemotherapy regimens and there is a possibility of confounding effects of the heterogeneous therapeutic modalities. Future studies with more detailed treatment information could elucidate the potential interaction between inherited genetic variation and treatment response.
In summary, genetic variants rs9929218 at 16q22.1 and rs10795668 at 10p14 may exert some influence in modulating patient's survival and they deserve to be further tested in additional CRC cohorts in order to confirm their potential as prognosis or predictive biomarkers.
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